This is an aggregated industry headline. Read the full story at BioPharma Dive →
Verge, following trial failure, rebrands its AI drug discovery ambitions
Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match potential brain drugs to patients who best benefit from them.
By BioPharma Dive
· May 27, 2026
· via BioPharma Dive
Image: BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Insulet and Calm are integrating mental health care into diabetes treatment with a series of mindfulness, medi…
The WeekFierceBiotech ↗
Spero pivots to I&I with $1.1B deal for Innovent antibody, sells slice of Utebzi royalties for $105M
Spero Therapeutics is pivoting to immune and inflammation indications through a license agreement for a CD40L …
The WeekBriefing
Jemperli met its main goal in a phase 2 trial for certain rectal cancers, and GSK now plans to seek U.S. appro…